Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer
نویسندگان
چکیده
منابع مشابه
Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
Postmenopausal patients with hormone-sensitive early breast cancer are typically treated with adjuvant endocrine therapy, which significantly reduces the risk of recurrence. Because treatment is of a long duration, side effects from adjuvant therapy can be problematic. The aromatase inhibitors (AIS) are replacing tamoxifen as first-line treatment agents for early breast cancer. Here, we present...
متن کاملUse of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer at German Breast Cancer Centers and University Hospitals - Results of an Enquiry (Adjuvant Endocrine Therapy Enquiry).
BACKGROUND: Many studies about the adjuvant endocrine therapy of postmenopausal patients with hormone receptor-positive breast cancer have shown significant superiority of aromatase inhibitors (AIs) compared to tamoxifen only. Within these studies, different AIs (anastrozole, letrozole, exemestane) and treatment strategies (upfront, switch, extended adjuvant) were applied. MATERIAL AND METHODS...
متن کاملUpdates on Adjuvant Therapy for Early Stage Hormone Receptor-Positive Breast Cancer
Adjuvant Chemotherapy in Hormone Receptor-Positive Disease: To Give or not to Give Chemotherapy in Hormone Receptor-Positive Disease Adjuvant chemotherapy for early-stage breast cancer was first described in the 1970s, with systemic cytotoxic chemotherapy demonstrating an improvement in survival in patients with early stage disease. Although adjuvant chemotherapy may benefit some patients, not ...
متن کاملAdjuvant endocrine therapy for postmenopausal women with early breast cancer.
Results from multiple clinical trials involving aromatase inhibitors have added to the knowledge base relating to endocrine therapy of postmenopausal women with hormone receptor-positive early breast cancer. In the extended adjuvant setting, data from the Austrian Breast and Colorectal Cancer Study Group 6a trial showed an advantage for anastrozole following 5 years of tamoxifen treatment, cons...
متن کاملAn updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
The third-generation aromatase inhibitors (AIS) are largely replacing tamoxifen in the adjuvant treatment of early-stage breast cancer in postmenopausal women with hormone receptor-positive tumours. To date, multiple trials have been conducted comparing tamoxifen treatment with an AI, and all have demonstrated improved disease-free survival with AI treatment. Trials have included direct 5-year ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Oncology
سال: 2016
ISSN: 1040-8746,1531-703X
DOI: 10.1097/cco.0000000000000323